Plain-English translation of NCT07447986 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called SG301, given as a subcutaneous injection (a shot under the skin), to see if it can help people with systemic lupus erythematosus (SLE) — a serious autoimmune disease where the body's immune system attacks its own tissues. The study will compare the medication against a placebo (a dummy injection with no active medicine) to measure whether the treatment reduces disease symptoms and activity.
Many people with lupus don't respond well enough to standard treatments or can't tolerate them. This medication targets a specific part of the immune system in a new way, offering hope for patients who need better treatment options.
You likely qualify if…
You likely don't qualify if…
You would receive either the new SG301 injection or a placebo injection at regular visits over several months. The study is double-blind, meaning neither you nor the research team will know which treatment you're receiving. You'll have blood tests to measure your lupus activity, check how your body is responding, and monitor for any side effects. The research team will assess your disease using a standard scoring system to determine whether the treatment is helping.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China